Tumor Models

Tumor Models

WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.

• A large collection of cell line-derived xenograft (CDX) tumor models with an imaging based orthotopic/metastatic CDX platform covering 16 tumor types
• Patient-derived xenograft (PDX) tumor models covering 20 cancer types, drug resistant model and mouse clinical trial enabling translational research
• Syngeneic tumor models covering 20 cancer types, enabled with immunotherapy SOC, TIL analysis and RNAseq profiling.
• Human immune checkpoint gene KI mouse models
• hPBMC/HSC humanized models
• Extensive panel of c-MET related CDX and PDX tumor models

Cell line-derived xenograft (CDX) tumor models

• 320+ validated models covering 30 tumor types
• 77+ cell lines derived from PDX models
• Available data of sensitivities to SOC (standard of care)
• Imaging-based orthotopic/metastatic tumor models
• Brain/bone metastatic models of lung/breast cancer cell lines

41 Luciferase Labelled Orthotopic/Metastatic Tumor Models

• Covering 17 tumor types
• Bioluminescent imaging system in SPF barrier

Patient-derived xenograft (PDX) tumor models

• 1,400+ PDX models covering full range of cancer types
• Fully-characterized models with genetic, molecular and pharmacological profiling
• Drug-resistant models, including a clinical acquired capmatinib-resistant LU-01-0751 lung cancer PDX model
• in vitro screening and derivative PDXC/PDXO models
• IO-PDX panel with hPBMC humanization

A Comprehensive PDX Collection of Asia Prevalent Tumors with Genomic Profiling

Syngeneic tumor models

• 87 Syngeneic models (mouse, rat, hamster) covering 20 cancer types
• Comprehensive panel of orthotopic syngeneic tumor models
• Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
• Tumor-infiltrating leukocytes (TILs) map
• WES, RNA-seq and scRNA-seq characterization

Genetically engineered models

• 48 engineered cell lines based on construct overexpression or gene knock-in
• Pharmacologically validated both in vitro and in vivo
• Focusing on drug-resistant mutation introduction and IO-related checkpoint humanization
• Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1

hPBMC/HSC Humanized Models

hPBMC Humanized Models

• Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
• Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
• Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

• Available humanized models from CIEA, combined with WuXi PDX/CDX models.
• Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

Established CDX/PDX-hPBMC Models

Drug-resistant models

• Engineered cell line derived xenograft models
• Acquired drug-resistant CDX and PDX models
• Intrinsic drug-resistant PDX models
• Resistant models harboring specific oncogenic drivers
• KRAS G12C drug resistant tumor models
• Extensive panel of CDK4/6 inhibitor resistant breast cancer models
• Clinical acquired capmatinib-resistant LU-01-0751 lung cancer PDX model
• Enzalutamide-resistant (LNCAP AR-F877L) mutation KI prostate cancer model
• Drug-resistant cell lines and corresponding in vivo models using CRISPR-mediated knock-in technology (for targets including BTK and ESR1)